Despite CV risk reduction with LDL-c control with statins, there is a high percentage residual CV risk. Three speakers discuss the players in residual risk with a focus on triglycerides. Additionally, they present data of the REDUCE-IT trial with icosapent ethyl and provide guidance for implementation of icosapent ethyl in the management of patients with residual risk.
This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
This educational program consists of three presentations on EPA and triglycerides.
Reassessing the role of triglycerides in residual cardiovascular risk - Richard Hobbs, MD – Oxford, UK
The benefits of icosapent ethyl in addressing residual risk: What is the evidence? - Lale Tokgözoğlu, MD – Ankara, Turkey
Integrating icosapent ethyl in preventive strategies: Practical guidance - Victor Aboyans, MD, PhD – Limoges, France
For questions regarding this activity, please contact us at info@pace-cme.org.
This educational activity is designed for all healthcare professionals with an interest in management of patients with residual risk.
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Funding for this educational program was provided by an unrestricted educational grant received from Amarin.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
Release Date:
Expiration Date:
